Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xencor, Inc. (XNCR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, Xencor uses its SEC filings to report material events, financial results and key corporate developments related to its XmAb® technology platform and pipeline.
Investors can review Form 8-K filings in which Xencor reports quarterly financial results, such as revenue from collaborations, milestones and royalties, research and development expenses, and cash and marketable securities balances. These filings often incorporate press releases that summarize progress in clinical programs like XmAb819, XmAb541, plamotamab, XmAb657, XmAb942 and XmAb412, as well as updates on partnered programs and royalty-bearing products.
Xencor’s SEC filings also cover corporate actions and governance changes, including board appointments and director compensation, and Regulation FD disclosures related to investor presentations and webcasts. For example, the company has filed 8-Ks to furnish presentation materials and press releases discussing initial Phase 1 results of XmAb819 and early data from XmAb541, along with associated clinical timelines.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in each document, helping readers quickly understand the implications of new information. Users can monitor real-time updates from EDGAR, track items related to financial condition, material clinical data disclosures, and governance events, and use the structured view of XNCR filings to follow how Xencor’s antibody engineering business and pipeline are reflected in its regulatory reporting.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in Xencor Inc. common stock. As of the event date of 12/31/2025, State Street reports beneficial ownership of 4,507,254 shares, representing 6.3% of Xencor’s outstanding common stock.
State Street reports no sole voting or dispositive power, with 4,308,425 shares under shared voting power and 4,507,254 shares under shared dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Xencor.
Xencor Inc. senior vice president and chief scientific officer John R. Desjarlais exercised a stock option for 5,322 shares of common stock on January 23, 2026. The option had an exercise price of $12.51 per share and had fully vested under a schedule beginning January 26, 2016. Following the exercise, Desjarlais directly owned 248,207 shares of Xencor common stock. The derivative position reported as a stock option now shows zero options remaining, reflecting the exercise of this expiring grant and no reported sale of the underlying shares.
Xencor, Inc. reports a preliminary estimate that its cash, cash equivalents and marketable debt securities totaled approximately $611 million as of December 31, 2025, compared with $706.7 million as of December 31, 2024. The company states that, based on its current operating plans, this cash position is expected to fund its research and development programs and operations through 2028. These figures are preliminary, unaudited and may change when year-end closing and auditing procedures are completed.
Xencor reported Q3 results with revenue of $20,999 from collaborations, milestones and royalties, down the P&L to an operating loss of $47,519. A strong swing in other income, including $44,201 of gains on marketable equity securities, narrowed the quarter’s net loss to $6,027.
Year to date, revenue reached $97,339, aided by Incyte milestones of $12,500 and $25,000 triggered by U.S. regulatory events. Research and development expense was $54,367 in Q3, and the company recorded asset impairment charges of $1,565 tied to pausing certain programs. Liquidity comprised cash and cash equivalents of $28,291, marketable debt securities of $358,493 current and $247,158 long term, and marketable equity securities of $84,260. Liabilities related to prior royalty sales declined to $133,138 after $55,037 of payments to OMERS. Net cash used in operating activities was $83,406 for the nine months. Shares outstanding were 71,410,469 as of October 30, 2025. The at‑the‑market facility remained unused, and pre‑funded warrants from September 2024 remain exercisable.
Xencor, Inc. furnished a Form 8-K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1.
The company stated this information is being furnished and shall not be deemed to be filed under the Exchange Act. The filing also includes the cover page interactive data file.
Xencor, Inc. furnished an update under Regulation FD. The company held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines.
Supporting materials were furnished, not filed, including a presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The presentation is stated to be current as of April 29, 2025. The company noted that these materials are incorporated by reference as furnished under Item 7.01 and are not deemed filed for Section 18 purposes.
Primecap Management reports beneficial ownership of 10,527,322 shares of Xencor common stock, representing 14.79% of the class. The filing states Primecap has sole voting power and sole dispositive power over these shares, with no shared voting or dispositive power reported.
The statement certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of Xencor. The filing also identifies the PRIMECAP Odyssey Aggressive Growth Fund as having an interest exceeding 5% of Xencor's outstanding common stock.
Xencor, Inc. (XNCR) – Form 4 insider filing, dated 31 Jul 2025. Independent director Raymond J. Deshaies received a single equity award and reported no open-market purchases or sales.
- Transaction: One stock option granting the right to buy 110,422 common shares at an exercise price of $8.32.
- Vesting: 1⁄3 of the option (36,807 shares) vests on 31 Jul 2026; the remaining 73,615 shares vest in equal monthly installments over the next 24 months. Expiration: 31 Jul 2035.
- Post-transaction holdings: Deshaies now beneficially owns 110,422 derivative securities; no non-derivative share ownership was reported.
The filing reflects a routine director incentive grant with a 10-year life and service-based vesting. It does not involve immediate cash outflow by the insider, nor does it signal open-market sentiment. Potential dilution is minimal relative to Xencor’s ~60 million shares outstanding, but the award aligns the director’s interests with long-term shareholder value.